YD BIO LTD
YDESNASDAQTrading Snapshot
- Day Range
- $7.44 – $7.61
- 52-Week Range
- $1.70 – $22.00
- Volume
- $2.15B
- Avg Volume
- $1.93B
- Shares Outstanding
- 70.8M
- Next Earnings
- Nov 29, 2026
Fundamentals Snapshot
- Annual Revenue
- $596,817
- Last Q Revenue
- $157,829
- P/E Ratio
- -4.5
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.64
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −15.5%
Why Investors Own YDES
- ✓High-growth profile — revenue up +24.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
YD BIO LTD
YDES
StockOtter · stockotter.spaceAbout YD BIO LTD
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
YD Bio Limited (NASDAQ:YDES) Sees Large Increase in Short Interest
YD Bio Limited (NASDAQ: YDES - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 15th, there was short interest totaling 42,960 shares, an increase of 223.2%
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovati
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
TAIPEI, Taiwan, Aug. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovati
Head-To-Head Comparison: YD Bio (NASDAQ:YDES) versus Arbutus Biopharma (NASDAQ:ABUS)
Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the st
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- Y
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovati